Status:
COMPLETED
Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice
Lead Sponsor:
AbbVie
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
A study to assess the real-life management and use of healthcare resources during the initiation of: * Venetoclax in combination with rituximab is indicated for the treatment of adult participants wi...
Eligibility Criteria
Inclusion
- Patient's physician prescribed venetoclax as per product monograph independent of the patient participation in this study.
- Has chronic lymphocytic leukemia (CLL) and has received at least one prior therapy.
Exclusion
- Currently participating in an interventional study.
- Has other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of CLL.
Key Trial Info
Start Date :
January 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT03310190
Start Date
January 10 2018
End Date
April 30 2022
Last Update
March 30 2023
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary /ID# 166416
Calgary, Alberta, Canada, T2N 4Z6
2
Cross Cancer Institute /ID# 166417
Edmonton, Alberta, Canada, T6G 1Z2
3
Jack Ady Cancer Centre /ID# 217491
Lethbridge, Alberta, Canada, T1J 1W5
4
CancerCare Manitoba /ID# 170751
Winnipeg, Manitoba, Canada, R3E 0V9